The panel recommends the FDA approve the Augment Bone Graft for use as an alternative to autograft in hindfoot and ankle fusions. The panel also voted 10-8 that Augment demonstrates a favorable benefit to risk profile for the indication.
The FDA will consider these recommendations when completing its review of the company’s premarket approval application. The product has Level 1 data supporting its safety and efficacy as a fully synthetic bone growth factor replacement for autograft.
Read the report on the advisory committee’s vote.
Related Articles on BioMimetic:
BioMimetic Therapeutics Posts $8M Net Loss in Q1
Millennium Research Group: Bone Graft Substitute Market to Reach $2.3B by 2015
FDA to Review Premarket Approval Application for BioMimetic
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
